Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
1 finding from 1 review
Bradycardia · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower bradycardia compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Number of patients with postoperative nausea and vomiting (24 hours postoperatively) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) may leads to lower PONV compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Overall signs of postoperative residual paralysis · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower overall signs of postoperative residual paralysis compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Risk of serious adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) showed no clear difference in risk of serious adverse eventsb compared with neostigmine (any dose) (low certainty).
1 finding from 1 review
Recovery timea from post‐tetanic count (PTC) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from post‐tetanic count (PTC 1 to 5) to train‐of‐four ratio (TOFR) > 0.9 (deep block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
1 finding from 1 review
Risk of adverse events and serious adverse eventsb, bradycardia, PONV, and signs of residual neuromuscular blockade · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from second twitch (T2) to train‐of‐four ratio (TOFR) > 0.9 (moderate block) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recovery timea from post‐tetanic count (PTC) · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of composite adverse eventsb · Adult patients, ASA I‐IV, who received non‐depolarizing NMBAs
Sugammadex (any dose) probably leads to lower risk of composite adverse eventsb compared with neostigmine (any dose) (moderate certainty).
1 finding from 1 review
Freedom from atrial arrhythmia · people with non‐paroxysmal atrial fibrillation
Ablation may leads to higher freedom from atrial arrhythmia compared with antiarrhythmic drug (low certainty).
1 finding from 1 review
Participants needing cardioversion · people with non‐paroxysmal atrial fibrillation
Ablation probably leads to lower participants needing cardioversion compared with antiarrhythmic drug (moderate certainty).
1 finding from 1 review
Cardiac hospitalisation Hospitalisations directly related to ablation or antiarrhythmic drugs · people with non‐paroxysmal atrial fibrillation
Ablation may leads to lower cardiac hospitalisation Hospitalisations directly related to… compared with antiarrhythmic drug (low certainty).
1 finding from 1 review
Significant bradycardia or need for a pacemaker · people with non‐paroxysmal atrial fibrillation
Ablation showed no clear difference in significant bradycardia or need for a pacemaker compared with antiarrhythmic drug (low certainty).
1 finding from 1 review
Perinatal mortality · Pregnant women in unselected or low‐risk populations.
All routine Doppler ultrasound showed no clear difference in perinatal death (stillbirth and neonatal death including anomalies) compared with no Doppler ultrasound (low certainty).
1 finding from 1 review
Serious neonatal morbidity · Pregnant women in unselected or low‐risk populations.
All routine Doppler ultrasound showed no clear difference in serious neonatal morbidity compared with no Doppler ultrasound (low certainty).
1 finding from 1 review
Caesarean section · Pregnant women in unselected or low‐risk populations.
All routine Doppler ultrasound showed no clear difference in caesarean section (elective and emergency) compared with no Doppler ultrasound (high certainty).
1 finding from 1 review